1. Home
  2. FLYX vs CING Comparison

FLYX vs CING Comparison

Compare FLYX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo flyExclusive Inc.

FLYX

flyExclusive Inc.

HOLD

Current Price

$1.37

Market Cap

62.1M

Sector

Finance

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.23

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYX
CING
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.1M
64.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
FLYX
CING
Price
$1.37
$5.23
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
410.4K
132.2K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
5.61
56.47
EPS
N/A
N/A
Revenue
$375,877,000.00
N/A
Revenue This Year
$10.47
N/A
Revenue Next Year
$15.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.85
N/A
52 Week Low
$1.05
$3.16
52 Week High
$8.88
$11.89

Technical Indicators

Market Signals
Indicator
FLYX
CING
Relative Strength Index (RSI) 51.94 58.37
Support Level $1.05 $5.08
Resistance Level $2.73 $5.54
Average True Range (ATR) 0.09 0.27
MACD 0.04 0.03
Stochastic Oscillator 88.46 82.22

Price Performance

Historical Comparison
FLYX
CING

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: